Navigation Links
Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
Date:11/17/2010

ained at the Cardiovascular Center in Aalst (Aalst, Belgium).

In accordance with the Bayh-Dole Act, Mayo Clinic has licensed the technology underlying C-Cure to Cardio 3 Biosciences and received an equity position in the company in the context of the license. Mayo Clinic, and the inventors of the technology, Drs. Andre Terzic and Atta Behfar, have a financial interest associated with the technology related to this research. While no royalties have accrued to date, Mayo Clinic has rights to receive future royalties which will be shared with Drs. Terzic and Behfar in accordance with Mayo Clinic Royalty Sharing policy.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or rep
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
2. Cardio3 BioSciences Announces Promising Pre-Clinical Data for Proprietary C-Cath(R) Catheter
3. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
4. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
6. Magellan Biosciences to Debut Revolutionary New Dynex® Clinical Diagnostics Processing System for Fully Automated ELISA Testing at MEDICA 2010
7. Sangamo BioSciences Announces Presentation at Lazard Capital Markets Healthcare Conference
8. Ambit Biosciences Strengthens Board of Directors and Executive Team
9. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
10. Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
11. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Chief Executive Officer, Doug Godshall , is scheduled ... Conference at 8:30 a.m. EDT on Thursday, August 13, ... at the InterContinental Boston. A live webcast ...
(Date:8/4/2015)... Aug. 04, 2015 ... the addition of the "MRI Systems Market ... Operational Efficiency, with Growth Driven by Developing Economies" ... Systems Market to 2020 - Focus on Patient ... Developing Economies" discusses the market, competitive landscape, and ...
(Date:8/4/2015)...  Dr. Keesha Ewers of The ... of flibanserin, or what is being touted as ... decreased female sexual desire back several decades. Diminished ... addressing libido as a singular symptom with a ... Photo - http://photos.prnewswire.com/prnh/20150804/254705 ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... Conn., Oct. 6 The Hedgeye Risk Management Healthcare team, led ... Conference Call, "Aging of America: Demographics of Demand and Profits in ... long tail of demographics, why 1994-2002 was so good, and why ... device demand, and the outlook for hip, knee, and spine device ...
... Oct. 6 Roxane Laboratories, Inc. announced today ... (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg ... Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. ... for immediate shipment to wholesalers and pharmacies nationwide. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July 27th by ... viable method for encouraging people to lose weight. Specifically the study compared control patients ... loss success, adding a financial incentive to the overall incentive of increased health. According ...
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts ... new book, The Pain Antidote , which provides strategies for people who suffer ... Center’s Chronic Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... immunizations, especially those entering kindergarten. All required immunizations are covered for members under ... means that children who aren’t caught up with their immunizations may not be ...
(Date:8/4/2015)... Hills, CA (PRWEB) , ... August 04, 2015 ... ... personal consultation complete with full examination now offered by the world renowned ... more beautiful aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... According to the findings of a UCSF study to ... journal "Obstetrics and Gynecology," the risk of miscarriage in ... // or chromosomal abnormalities is lower than previously believed. ... common prenatal tests performed during the first and second ...
... a person grows old, the functioning of his lungs weakens. According ... ,An 8-year study was conducted on 670 men, 45 – 86 ... of long-standing anger at the beginning of the project had notably ... study is one of the first to show prospectively that hostility ...
... turn out to be the worst enemy for asthmatic ... response to air pollution says a recent study.// This ... chronic cough, phlegm production (bronchitis) and dog & cat ... preventive medicine at the University of Southern California's Keck ...
... colon polyps to half, it doubles the risk of serious ... studies published in the Aug. 31 issue of The New ... M.D., Ph.D., and John D. Potter, M.B., Ph.D., of the ... ,"These two trials provide strong evidence that among patients ...
... Physical activity after a high-fat meal not only reverses the ... //of these same arteries compared to before the meal, according ... in the European Journal of Applied Physiology, are part of ... body after the meal -- also known as the postprandial ...
... brain areas preoperative brain could effectively alter the outcome ... appear in the September issue of Radiology, states that ... the brain with functional magnetic resonance imaging (fMRI), could ... effectively, and could also reduce the risk of damaging ...
Cached Medicine News:Health News:Prenatal Test and Miscarriage 2Health News:Prenatal Test and Miscarriage 3Health News:Dogs aggravate asthma in kids 2Health News:Celebrex- pros and cons 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
Inquire...
Inquire...
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: